Humacyte

Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions. The company has developed a scalable bioengineering platform that transforms human cells into universally implantable human tissues being investigated for the treatment of injury, disease, and chronic conditions across a wide range of clinical needs.

Humacyte's first FDA-approved product, Symvess (acellular tissue engineered vessel-tyod), is a first-in-class bioengineered human tissue designed for vascular trauma repair. The company's extensive pipeline includes Acellular Tissue Engineered Vessels for applications such as dialysis access and peripheral arterial disease, Advanced Organ Systems including BioVascular Pancreas for Type 1 diabetes and lung applications, and Advanced Tissue Constructs for tracheal, esophageal, and urinary conduit replacements. Founded in 2004 and headquartered in Durham, North Carolina, Humacyte is committed to bringing first-in-class regenerative medicine products to market and transforming the future of medicine.